Brand Name
Zemuron
Broad Category
Nondepolarizing neuromuscular blocking agent (NMBA)
Pharmacological class
Aminosteroid
MOA
Presynaptic: prevents release of ACh
Postsynaptic: binds to one or both alpha subunits of nicotinic acetylcholine receptor on motor endplate blocking acetylcholine from binding
Indications
Volume of distribution
small confined to ECF
CV effects?
Highly stable
Resp effects
paralysis
Histamine release?
Rare to none
Allergic reaction?
second major cause of anaphylaxis
Reversals?
Considerations (receptor upregulation)
Denervation, burns, trauma, immobility, hemiplegia etc results in upregulations of immature extrajunctional nicotinic ACh receptors, resulting in RESISTANCE
Considerations (down regulation)
Myasthenia gravis results in fewer ACH receptors resulting in INCREASED sensitivity
Precautions
Hepatic impairment
Pregnancy Duration?
Prolonged and more sensitive, need reduction of dosing
Elderly considerations
Prolonged duration due to decreased liver capacity
Normal induction
0.6 mg/kg
(0.3-1.1)
RSI dosing
1.2 mg/kg
Infusion dosing
5-12 mcg/kg/min
Defasiculation dose
5 mg
Maintenance Bolus dosing
0.1 - 0.2 mg/kg
Onset
1-2 mins
Duration
30-70 mins
dose dependent
Metabolism
Insignificant or none